Research Reports

Key takeaways

Compensation Committee approved 100,000 restricted stock shares to James Parslow on April 21, 2026.

7,000 shares vest immediately; 31,000 shares vest annually on first, second, and third anniversaries.

Vesting requires continued service; full acceleration upon Change in Control.

Grant under Amended and Restated Equity Incentive Plan; details in Exhibit 10.1.

Parslow serves as Interim Chief Executive Officer and Chief Financial Officer.

Full analysis

The grant to James Parslow, who holds dual roles as Interim CEO and CFO, aligns executive incentives with shareholder interests through time-based vesting tied to continued service. The structure provides immediate liquidity for 7% of the award while deferring the balance over three years, with full acceleration on a Change in Control to protect the executive in potential transactions. This compensatory arrangement, approved by the Compensation Committee, is governed by the company's Amended and Restated Equity Incentive Plan and detailed in Exhibit 10.1.

XBIO · Xenetic Biosciences, Inc.

Summary

Key takeaways

Full analysis